Isolation of CYP3A4 Inhibitors from the Black Cohosh (Cimicifuga racemosa)

Sachiko Tsukamoto, Maki Aburatani and Tomihisa Ohta

Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan

Recent investigation on drug interaction has shown that some foods and herbal medicines increase the oral availability of a variety of CYP3A4 substrates, which is caused by the reduction of CYP3A4 in intestinal epithelium. During the course of our investigation on CYP3A4 interaction, we found that the commercially available dietary supplement made from black cohosh (Cimicifuga racemosa) showed CYP3A4 inhibition. Black cohosh has been used for the treatment of menopausal and post-menopausal symptoms as a dietary supplement. Bioassay-guided isolation from the supplement afforded six active principles, which were identified as cycloartanoid triterpene glycosides.

Keywords: black cohosh – Cimicifuga racemosa – CYP3A4 – cytochrome P450 – inhibition – triterpene glycoside
Isolation of Triterpene Glycosides 1–6 from *C. racemosa*

Commercially available black cohosh, *C. racemosa* Nutt, was generously provided by from Tokiwa Phytochemical Co., Ltd. (Japan). The powder of black cohosh (20 g) was suspended in water and extracted with ethyl acetate (EtOAc). The organic layer was then partitioned between hexane and 90% methanol (MeOH)-H2O. The polar fraction (6.1 g), which exhibited significant CYP3A4 inhibition, 44% at 5 mg/ml, was subjected to silica gel chromatography with EtOAc/MeOH followed by octadecyl silica gel (ODS) chromatography with MeOH/H2O and then acetonitrile (CH3CN)/H2O to afford a potent CYP3A4 inhibitory fraction. The purification by ODS high-performance liquid chromatography (HPLC) with CH3CN/H2O gave six triterpene glycosides 1–6. On the basis of 1H NMR spectra in C5D5N and fast atom bombardment mass spectrometry (FABMS), the six triterpene glycosides were identified as cimiracemoside H (1, 2.0 mg, 0.01% yield) (19), 26-deoxyactein (2, 1.1 mg, 0.0055%) (20,21), 23-O-acetylshengmanol 3-O-H9252-D-xylopyranoside (3, 1.9 mg, 0.0095%) (22), actaeaepoxide 3-O-H9252-D-xylopyranoside (4, 1.1 mg, 0.0055%) (23), 25-O-acetylcimigenol 3-O-H9251-L-arabinopyranoside (5, 5.9 mg, 0.029%) (24) and 25-O-acetyl-cimigenol 3-O-D-xylopyranoside (6, 4.2 mg, 0.021%) (25,26) (Figure 1).

Assay of CYP3A4 Inhibition

CYP3A4 activity was based on nifedipine oxidation. Various amounts (0–10 μM, final concentration) of samples in 1 μl of dimethylsulfoxide (DMSO) were added to 192 μl of solution containing 100 mM phosphate buffer (pH 7.4) containing 50 μM nifedipine (Wako Pure Chemical Industries, Ltd, Osaka, Japan), 5 mM glucose-6-phosphate (Oriental Yeast Co., Ltd, Tokyo, Japan), 0.5 mM β-NADP+ (Oriental Yeast Co., Ltd), 0.5 mM MgCl2 and 4.3 μg/ml glucose-6-phosphate dehydrogenase (Oriental Yeast Co., Ltd) and incubated at 37°C for 5 min. CYP3A4 (Gentest Co., Woburn, MA) was also pre-incubated in 7 μl of the buffer at 37°C for 5 min and added to the sample solution. After the incubation at 37°C for 1 h, the reaction was quenched by the addition of 100 μl of MeOH. After adding 3.7 μg of 6-methoxy carbonyl-5-methyl-7-(2-nitrophenyl)-4,7-dihydrofurone[3,4-b]pyridin-1-(3H)-one in 1 μl of DMSO as an internal standard, the reaction mixture was extracted with 1 ml of ether, and the ether layer was evaporated. The residue was dissolved in 100 μl of MeOH, and an aliquot (20 μl) was analyzed by reverse-phase HPLC (column, TSK-gel ODS-120T, 4.6 mm i.d. × 150 mm; mobile phase, 64% MeOH-H2O; flow rate, 1.0 ml/min; detection, UV 254 nm); retention times: 2.9 min for the internal standard, 4.0 min for the nifedipine metabolite (nifedipine pyridine) and 5.5 min for nifedipine. The IC50 value, the concentration required for 50% inhibition of CYP3A4 activity, was calculated from the data of duplicate measurements.

Results

Bioassay-guided Isolation of Triterpene Glycosides 1–6 from *C. racemosa*

The CYP inhibition was tested using human CYP3A4 as shown in Methods. Commercially available supplement of *C. racemosa* was extracted with EtOAc, and the organic layer was then partitioned between hexane and 90% MeOH-H2O. The polar fraction exhibited significant CYP inhibition. Forty-four percent inhibition at 5 mg/ml was as potent as that by ketoconazole, 58% at 5 μg/ml. Bioassay-guided fractionation afforded six triterpene glycosides 1–6. On the basis of their 1H NMR spectra in C6D6N and FABMS, they were identified as cimiracemoside H (1, 0.01% yield) (20), 26-deoxyactein (2, 0.0055%) (21,22),
Table 1. CYP3A4 inhibition of C. racemosa metabolites

| Compound | IC50 (mM) |
|----------|-----------|
| 1        | 0.48      |
| 2        | 0.10      |
| 3        | 0.11      |
| 4        | 7.78      |
| 5        | 1.4       |
| 6        | 0.83      |
| Ketoconazole\(^a\) | 0.00011     |

\(^a\)A typical CYP3A4 inhibitor.

23-O-acetylshengmanol 3-O-β-D-xylopyranoside (3, 0.095%) (23), actaeapoxide 3-O-β-D-xylopyranoside (4, 0.0055%) (24), 25-O-acetylcamigenol 3-O-α-L-arabinopyranoside (5, 0.0029%) (25) and 25-O-acetylcamigenol 3-O-β-D-xylopyranoside (6, 0.0021%) (26,27). The CYP inhibitory activities of 1–6 are shown in Table 1, which indicates moderate IC50 values.

**Discussion**

Bailey *et al.* demonstrated that the blood concentration of anti-hypertensive drugs such as nifedipine was kept at a high level with grapefruit juice co-administered to mask the taste of alcohol. Since that time there has been a great deal of interest in food–drug interactions because of the clinical risks associated with changes in the bioavailability or metabolic rate of clinically administered drugs. In spite of the increasing use of herbal remedies and nutraceuticals, information on the drug interaction that occurs with them including foodstuffs, is still insufficient to understand the clinical risks.

We have studied drug interactions with foodstuffs such as grapefruit juice and pepper, isolating several potent CYP3A4 inhibitors in each material. The fact that a foodstuff contains more than one inhibitor suggests that the clinical effect of drug inhibitors in each material. The fact that a foodstuff contains grapefruit juice and pepper, isolating several potent CYP3A4 inhibitory principles. To date, highly potent CYP3A4 inhibitors in food have been reported, e.g. paradisins A and B (IC50, 0.07 and 0.07 μM) from grapefruit juice (15), dipiperamide A (IC50, 0.18 μM) from white pepper (17) and gomisin C (IC50, 0.254 μM) from Schisandra fruit (29).

Although the IC50 value of each isolate was moderate, the high content of a series of cognates in the supplement could result in the exhibition of significant CYP inhibition. Care should be taken to avoid concomitant intake of black cohosh with any kind of medication because of the possibility of increasing the bioavailable concentration of drugs in the blood by the down-regulation suppression of CYP3A4. Medical practitioners therefore should pay more attention in order to avoid any trouble with diet containing black cohosh.

The IC50, 0.027 mg/ml, of the extract of black cohosh was very low in spite of the weak activities of the isolated compounds. The IC50 value indicates that 40 mg of the black cohosh extract could be estimated to inhibit the metabolism of roughly half a dose of nifedipine for 1 day.

Evaluation of the IC50 of both constituents and the extract may be useful for clinical study of drug interactions of herbs and foodstuffs predicted to be a clinical risk, especially for the study of the mechanism of action and the pharmacokinetics.

**Acknowledgments**

The authors are grateful to Tokiwa Phytochemical Co., Ltd (Japan) for the generous gift of black cohosh.

**References**

1. New Medicinal College of Jiangsu (ed.). Dictionary of Chinese Materia Medica. Shanghai Scientific and Technological Press, Shanghai, 1977: p. 451.
2. Lieberman S. A review of the effectiveness of *Cimicifuga racemosa* (black cohosh) for the symptoms of menopause. *J Women’s Health* 1998;7:525–29.
3. McKenna D, Jones K, Humphrey S, Hughes K. Black cohosh: efficacy, safety, and use in clinical and preclinical applications. *Altern Ther Med* 2001;7:93–100.
4. Borrelli F, Izzo AA, Ernst E. Pharmacological effects of *Cimicifuga racemosa*. *Life Sci* 2003;73:1215–29.
5. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Gunsalus IC, Nebert DW. *P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature*. *Pharmacogenetics* 1996;6:1–42.
6. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther* 1994;270:414–23.
7. Guengerich FP. Role of cytochrome P450 enzymes in drug–drug interactions. *Adv Pharmacol* 1997;43:7–35.
8. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. *Drug Metab. Rev.* 1997;29:413–580.
9. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. *Clin Pharmacol Ther* 1995;57:485–91.
10. Yee GC, Stanley DL, Pessa LJ, Dalla CT, Beltz SE, Ruiz J. Effect of grapefruit juice on blood cyclosporin concentration. *Lancet* 1995;345:955–56.
11. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahnenhuh S. Interaction between grapefruit juice and midazolam in humans. *Clin Pharmacol Ther* 1995;58:20–8.
12. Bailey DG, Arnold JM, Spence JD. Grapefruit juice and drugs. How significant is the interaction? *Clin Pharmacokinet* 1994;26:91–8.
13. Hukkanen SK, Varhe A, Ollkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. *Clin Pharmacol Ther* 1995;58:127–31.
14. Ohba T, Nagahashi M, Hosoi S, Tsukamoto S. Dihydroxybergamottin caprate as a potent and stable CYP3A4 inhibitor. *Biorg Med Chem* 2002;10:969–73.
15. Ohba T, Maruyama T, Nagahashi K, Miyamoto Y, Hosoi S, Kiuchi F, Yamazoe Y, Tsukamoto S. Paradisin C: a new CYP3A4 inhibitor from grapefruit juice. *Tetrahedron* 2002;58:6631–35.
16. Ohba T, Miyamoto Y, Maruyama T, Kiuchi F, Tsukamoto S. Localization and contents of paradisins, the most potent CYP3A4 inhibitors, in a
g grapefruit Citrus paradisi and grapefruit juice. Nat Med 2002;56: 264–7.

17. Tsukamoto S, Cha B-C, Ohta T. Dipiperamides A, B, and C: bisalkaloids from the white pepper Piper nigrum inhibiting CYP3A4 activity. Tetrahedron 2002;58:1667–71.

18. Tsukamoto S, Tomise K, Miyakawa K, Cha B-C, Abe T, Hamada Y, Hirota H, Ohta T. CYP3A4 inhibitory activity of new bisalkaloids dipiperamides D and E and cognate alkaloids from the white pepper. Bioorg Med Chem 2002;10:2981–85.

19. Tsukamoto S, Tomise K, Aburatani, M, Onuki H, Hirota H, Ishiharajima E, Ohta T. Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa Duch. cv. Tochiotome. J Nat Prod 2004;67(11): 1839–41.

20. Shao Y, Harris A, Wang M, Zhang H, Cordell GA, Bowman M, Lemmo E. Triterpene glucosides from Cimicifuga racemosa. J Nat Prod 2000;63: 905–10.

21. Koeda M, Aoki Y, Sakurai N, Nagai M. Studies on the Chinese crude drug ‘Shoma.’ IX. Three novel cycloanostanol xylosides, cimicifugosides H-1, H-2 and H-5, from Cimicifuga Rhizome. Chem Pharm Bull. 1995;43:771–6.

22. Chen S-N, Li W, Fabricant DS, Santarsiero BD, Mesecar A, Fitzloff JF, Fong HHS, Farnsworth NR. Isolation, structure elucidation, and absolute configuration of 26-deoxyactein from Cimicifuga racemosa and clarification of nomenclature associated with 21-deoxyactein. J Nat Prod 2002;65:601–5.

23. Kusano A, Shibano M, Kitagawa S, Kasano G, Nozoe S, Fushiya S. Studies on the constituents of Cimicifuga species. XV. Two new diglycosides from the aerial parts of Cimicifuga simplex WORMSK. Chem Pharm. Bull. 1994;42:1940–43.

24. Wende K, Mugge C, Throw K, Schopke T, Lindequist U, Actaeaepoxide 3-O-β-D-xlyopyranoside, a new cycloartane glycoside from the rhizomes of Actaea racemosa (Cimicifuga racemosa). J Nat Prod 2001;64: 986–9.

25. Ye W, Zhang J, Che C-T, Ye T, Zhao S. New cycloartane glycosides from Cimicifuga dahurica. Planta Med 1999;65:770–1.

26. Kadota S, Li JX, Tanaka K, Namba T. Constituents of Cimicifugiae rhizoma II. Isolation and Structures of new cycloartenol triterpenoids and related compounds from Cimicifuga foetida L. Tetrahedron 1995;51:1143–66.

27. Takemoto T, Kusano G, Kawahara M. Studies on the constituents of Cimicifuga spp. VI. Structures of 25-O-acetylimigenoside and 25-O-methylimigenoside. Yakugaku Zasshi 1970;90:64–7.

28. “The Pharmacopoeia of Chinese People’s Republic” vol. I, The People’s Health Publishing House & The Chemical Industry Publishing House, Beijing, 1990, p. 59.

29. Iwata H, Tetsuka Y, Kadota S, Hiratsuka A, Watabe T. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos 2004;32:1351–8.

Received September 30, 2004; revised January 18, 2005; accepted March 28, 2005